A possible prolactin-related adverse effect of certain antineoplastic anthracyclines

Toxicology Letters

Volumn 116, Issue 3, 2000, Pages 231-236

  Brunetti, Luigi ^a   Orlando, Giustino ^a   Michelotto, Barbara ^a   Recinella, Lucia ^a   Ragazzoni, Enzo ^b   Vacca, Michele ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anthracyclines; Daunorubicin; Doxorubicin; Epirubicin; Pituitary; Prolactin (PRL)

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; EPIRUBICIN; PROLACTIN;

ADENOHYPOPHYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; RAT;

ANIMAL; ANTIBIOTICS, ANTHRACYCLINE; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; EPIRUBICIN; MALE; PROLACTIN; RATS; RATS, WISTAR; SUPPORT, NON-U.S. GOV'T;

EID: 0034674890     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(00)00223-X     Document Type: Article

References (12)

1. Besedowski H.O., Del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr. Rev. 17:1996;64-102.
2. Brunetti L., Preziosi P., Ragazzoni E., Vacca M. Effects of vindesine on hypothalamic-pituitary-adrenal axis. Toxicol. Lett. 75:1995;69-73.
3. ++ exchange of dog heart sarcolemmal vesicles. FEBS Lett. 130:1981;184-186.
4. Chabner B.A., Allegra C.J., Curt G.A., Calabresi P. Antineoplastic agents. Hardman J.G., Limbird L.E., Ruddon R.W., Gilman A.G. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th edition :1996;1233-1287 McGraw Hill, New York.
5. Clevenger C.V., Chang W.P., Ngo W., Pasha T.L., Montone K.T., Tomaszewski J.E. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am. J. Pathol. 146:1995;695-705.
6. Fuh G., Wells J.A. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J. Biol. Chem. 270:1995;13133-13137.
7. Robert J. Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs. 45:(Suppl. 2):1993;20-30.
8. +-adenosine triphosphatase pump by ouabain. J. Pharmacol. Exp. Ther. 246:1988;682-688.
9. Tritton T.R., Murphee S.A., Sartorelli A.C. Adriamycin: a proposal on the specificity of drug action. Biochem. Biophys. Res. Commun. 84:1978;802-808.
10. Welsch C.W., Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res. 37:1977;951-963.
11. Wils J.A., Bliss J.M., Marty M., Coombes G., Fontaine C., Morvan F., Olmos T., Pérez-López F.R., Vassillopoulos P., Woods E., Coombes R.C. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J. Clin. Oncol. 17:1999;1988-1998.
12. Yeung S.J., Chiu A.C., Vassilopoulou-Sellin R., Gagel R.F. The endocrine effects of nonhormonal antineoplastic therapy. Endocr. Rev. 19:1998;144-172.